US 12,144,848 B2
Arginine depletion therapy for treatment of GAMT deficiency
Anthony G. Quinn, Gloucester, MA (US); Andreas Schulze, Toronto (CA); and Scott W. Rowlinson, Austin, TX (US)
Assigned to Immedica Pharma AB, Stockholm (SE)
Appl. No. 17/286,041
Filed by Aerase, Inc., Austin, TX (US)
PCT Filed Oct. 18, 2019, PCT No. PCT/US2019/057027
§ 371(c)(1), (2) Date Apr. 16, 2021,
PCT Pub. No. WO2020/081994, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,837, filed on Oct. 19, 2018.
Prior Publication US 2021/0379167 A1, Dec. 9, 2021
Int. Cl. A61K 38/50 (2006.01)
CPC A61K 38/50 (2013.01) [C12Y 305/03001 (2013.01); C12Y 305/03006 (2013.01)] 35 Claims
 
1. A method of treating a deficiency in guanidinoacetate methyltransferase (GAMT) activity in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutic amount of an arginine depleting enzyme, wherein the arginine depleting enzyme is a human arginase enzyme, a human arginine deiminase enzyme, or a combination thereof.